|
시장보고서
상품코드
2070374
펨브롤리주맙 시장 : 시장 규모, 점유율, 성장률, 업계 분석, 지역별 동향 및 예측(2026-2034년)Pembrolizumab Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
펨브롤리주맙 시장의 성장 요인
세계 펨브롤리주맙 시장은 2025년에 317억 달러로 평가되었고, 2026년 331억 달러에서 2034년까지 411억 달러로 성장할 것으로 예상되며, 예측 기간 동안 연평균 성장률(CAGR)은 2.74%에 달할 전망입니다. 주로 ‘KEYTRUDA’라는 상품명으로 판매되고 있는 펨브롤리주맙은 여러 유형의 암에 걸쳐 사용되는 주요 면역종양학 치료법 중 하나입니다. 이 약물은 면역 체계가 암세포를 인식하고 공격하도록 돕는 방식으로 작용합니다.
이 시장은 임상 현장에서의 적극적인 도입, 적응증의 지속적인 확대, 조기 치료 단계에서의 사용 증가, 그리고 바이오마커 기반 암 치료에 대한 수요 증가에 힘입어 꾸준히 성장하고 있습니다. 2025년에는 높은 암 발병률, 선진적인 종양학 인프라, 광범위한 바이오마커 검사, 그리고 탄탄한 보험 적용 체계에 힘입어 북미가 52.77%의 시장 점유율을 차지하며 시장을 주도했습니다.
펨브롤리주맙 시장 동향
시장의 주요 동향으로는 표준 암 치료에서 면역요법의 역할이 확대되고 있다는 점을 들 수 있습니다. 펨브롤리주맙은 진행성 암이나 전이성 암뿐만 아니라, 초기 단계나 수술 전후 치료 상황에서도 점점 더 많이 사용되고 있습니다. 이러한 폭넓은 도입으로 인해 의사의 신뢰도가 높아지고, 적합한 환자층이 확대되고 있습니다.
2025년 6월, 머크사는 PD-L1 양성인 절제 가능한 국소 진행성 두경부 편평상피암에 대한 KEYTRUDA의 수술 전 보조 치료 및 수술 후 보조 치료로 미국 FDA의 승인을 획득했습니다. 이는 체계화된 암 치료 경로에서 해당 약물의 역할이 더욱 공고해지고 있음을 보여줍니다.
시장 성장 촉진요인
시장 성장의 주요 요인은 전 세계적으로 증가하는 암 부담입니다. 폐암, 유방암, 대장암, 신장암, 방광암, 두경부암 및 부인과암의 환자 수가 증가하고 있으며, 이로 인해 첨단 전신 치료에 대한 수요가 늘어나고 있습니다. 펨브롤리주맙은 여러 유형의 종양에 대해 승인되어 있으며, 이것이 이 약물의 폭넓은 임상적 사용을 뒷받침하고 있습니다. 진단율의 상승, 바이오마커 검사의 보급, 그리고 조기 치료 개입 또한 치료 대상이 되는 환자층의 확대에 기여하고 있습니다.
시장 성장 억제요인
고액의 치료비와 보험 환급과 관련된 압박은 여전히 주요 제약 요인으로 작용하고 있습니다. 펨브롤리주맙은 고가의 생물학적 제제로, 엄격한 의료 기술 평가가 이루어지기 때문에 의료 예산이 제한된 국가에서는 치료 접근이 지연될 가능성이 있습니다. 보험 환급에 관한 협상, 가격 재검토 및 보험사의 제한 조치는 특히 비용에 민감한 시장에서 규제 당국의 승인 후에도 도입을 지연시키는 요인이 될 수 있습니다.
시장 기회
여러 종양 유형에 걸친 적응증 확대가 지속되면서 강력한 성장 기회를 가져오고 있습니다. 새로운 승인을 받을 때마다, 펨브롤리주맙은 추가적인 암 적응증, 치료 단계 또는 환자 하위 집단으로 적용 범위를 확대할 수 있게 됩니다. 2026년 2월, 머크사는 PD-L1 양성 백금 제제 내성 난소암, 난관암, 또는 원발성 복막암을 가진 특정 성인 환자를 대상으로, 파클리탁셀(베바시주맙 병용 여부와 관계없이)과의 병용을 통한 ‘KEYTRUDA’ 및 ‘KEYTRUDA QLEX’의 승인을 발표했습니다. 이러한 적응증 확대는 부인과 종양 분야에서의 추가적인 확산을 뒷받침할 것입니다.
시장의 과제
주요 과제는 바이오시밀러의 부상과 특허 만료로 인한 압박이 커지고 있다는 점입니다. 펨브롤리주맙은 전 세계적으로 매출 규모가 큰 고부가가치 생물학적 제제이기 때문에 바이오시밀러 개발 기업들이 이 분야에 적극적으로 진출하고 있습니다. 향후 바이오시밀러가 출시되면 가격 측면의 압박이 커지고, 시장 내 독점권이 축소되어 원개발사의 장기적인 매출 성장에 영향을 미칠 가능성이 있습니다. 2025년 6월, 닥터 레디와 알보텍은 세계 시장을 겨냥한 펨브롤리주맙 바이오시밀러를 공동 개발 및 상용화하기 위한 제휴를 발표했습니다.
지역별 분석
북미는 2025년에 167억 3,000만 달러를 기록하며, 2024년의 157억 7,000만 달러에서 증가해 세계 시장을 주도했습니다. 미국 시장은 2026년에 156억 4,000만 달러에 달할 것으로 추정되며, 전 세계 매출의 약 47.24%를 차지할 전망입니다.
유럽 시장은 2026년에 76억 달러에 달하며, 2.26%의 성장률을 보일 것으로 전망됩니다. 영국 시장은 13억 8,000만 달러로 추산되는 반면, 독일 시장은 2026년에 17억 달러에 달할 것으로 전망됩니다.
아시아태평양은 암 환자 수가 많고 항암제 접근성이 개선된 데 힘입어, 2026년에는 62억 4,000만 달러에 달할 것으로 전망됩니다. 2026년 시장 규모는 중국이 21억 6,000만 달러, 일본이 14억 6,000만 달러, 인도가 5억 1,000만 달러에 달할 것으로 예측됩니다.
라틴아메리카 시장은 2026년에 10억 9,000만 달러에 달할 것으로 예상되며, GCC 시장은 4억 달러로 전망됩니다. 남아프리카공화국의 규모는 2026년에 1억 9,000만 달러에 달할 것으로 전망됩니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 펨브롤리주맙 시장 분석, 인사이트 및 예측(2021-2034년)
제6장 북미의 펨브롤리주맙 시장 분석, 인사이트 및 예측(2021-2034년)
제7장 유럽의 펨브롤리주맙 시장 분석, 인사이트 및 예측(2021-2034년)
제8장 아시아태평양의 펨브롤리주맙 시장 분석, 인사이트 및 예측(2021-2034년)
제9장 라틴아메리카의 펨브롤리주맙 시장 분석, 인사이트 및 예측(2021-2034년)
제10장 중동 및 아프리카의 펨브롤리주맙 시장 분석, 인사이트 및 예측(2021-2034년)
제11장 경쟁 분석
AJYGrowth Factors of pembrolizumab Market
The global pembrolizumab market was valued at USD 31.70 billion in 2025 and is projected to grow from USD 33.10 billion in 2026 to USD 41.10 billion by 2034, registering a CAGR of 2.74% during the forecast period. Pembrolizumab, marketed mainly as KEYTRUDA, is one of the leading immuno-oncology therapies used across several cancer types. It works by helping the immune system recognize and attack cancer cells.
The market is growing steadily due to strong clinical adoption, continued label expansions, rising use in earlier treatment settings, and increasing demand for biomarker-driven cancer therapy. North America dominated the market in 2025 with a 52.77% market share, supported by high cancer incidence, advanced oncology infrastructure, broad biomarker testing, and strong reimbursement access.
Pembrolizumab Market Trends
A key trend in the market is the growing role of immunotherapy in standard cancer care. Pembrolizumab is increasingly being used not only in advanced and metastatic cancer but also in earlier-stage and perioperative treatment settings. This wider integration is strengthening physician confidence and expanding the eligible patient base.
In June 2025, Merck received U.S. FDA approval for KEYTRUDA in PD-L1 positive resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant and adjuvant treatment, showing its deeper role in structured cancer treatment pathways.
Market Drivers
The major driver of market growth is the rising global cancer burden. Increasing cases of lung, breast, colorectal, kidney, bladder, head and neck, and gynecologic cancers are driving demand for advanced systemic therapies. Pembrolizumab has approvals across multiple tumor types, which supports its broad clinical use. Growing diagnosis rates, wider biomarker testing, and earlier treatment intervention are also increasing the eligible treatment population.
Market Restraints
High treatment cost and reimbursement pressure remain key restraints. Pembrolizumab is a premium-priced biologic therapy, and access can be delayed in countries with strict health technology assessments and limited healthcare budgets. Reimbursement negotiations, pricing reviews, and payer restrictions can slow adoption even after regulatory approval, especially in cost-sensitive markets.
Market Opportunities
Continuous label expansion across multiple tumor types presents strong growth opportunities. Each new approval allows pembrolizumab to enter additional cancer settings, treatment lines, or patient subgroups. In February 2026, Merck announced approval for KEYTRUDA and KEYTRUDA QLEX with paclitaxel, with or without bevacizumab, for certain adults with PD-L1-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma. This expansion supports deeper penetration in gynecologic oncology.
Market Challenges
The main challenge is rising biosimilar and patent-cliff pressure. Since pembrolizumab is a high-value biologic with large global sales, biosimilar developers are actively entering the space. Future biosimilar launches may create pricing pressure, reduce market exclusivity, and affect long-term revenue growth for the originator brand. In June 2025, Dr. Reddy's and Alvotech announced a collaboration to co-develop and commercialize a pembrolizumab biosimilar for global markets.
Segment Analysis
By product type, the market is segmented into KEYTRUDA IV and KEYTRUDA QLEX/subcutaneous pembrolizumab. KEYTRUDA IV dominated the market due to its long-established use, strong clinical familiarity, infusion-based workflows, and broad adoption across tumor types. KEYTRUDA QLEX is expected to grow at a CAGR of 20.44% due to its convenient subcutaneous administration.
By disease indication, the NSCLC segment dominated in 2025 due to high disease burden and strong pembrolizumab adoption across advanced and earlier-stage lung cancer. The others segment is projected to grow at a CAGR of 4.93%.
By age group, the adult segment dominated the market in 2025, as most approved indications and commercial use are concentrated in adult solid tumors. The pediatric segment is projected to grow at a CAGR of 6.01%.
By type, the branded segment led the market, supported by KEYTRUDA's strong global approval base and absence of marketed biosimilar competition. The biosimilar segment is expected to grow at a CAGR of 45.90% during the study period.
By therapy setting, advanced/metastatic disease dominated due to pembrolizumab's long-standing use in late-stage oncology. The early-stage/perioperative segment is projected to grow at a CAGR of 6.27%.
By route of administration, the IV segment dominated, while the SC segment is emerging with new approvals. By end user, specialty cancer clinics led the market due to strong oncology expertise, biomarker-based treatment decisions, and immunotherapy administration capabilities.
Regional Analysis
North America led the global market with USD 16.73 billion in 2025, increasing from USD 15.77 billion in 2024. The U.S. market is estimated to reach USD 15.64 billion in 2026, accounting for about 47.24% of global revenue.
Europe is projected to reach USD 7.60 billion in 2026, growing at 2.26%. The U.K. market is estimated at USD 1.38 billion, while Germany is expected to reach USD 1.70 billion in 2026.
Asia Pacific is expected to reach USD 6.24 billion in 2026, supported by a large cancer patient base and improving access to oncology medicines. China is projected at USD 2.16 billion, Japan at USD 1.46 billion, and India at USD 0.51 billion in 2026.
Latin America is set to reach USD 1.09 billion in 2026, while the GCC market is projected at USD 0.40 billion. South Africa is expected to reach USD 0.19 billion in 2026.
Competitive Landscape
The global market is highly consolidated, led by Merck & Co., Inc. Other key players include Samsung Bioepis, Sandoz, Celltrion, Shanghai Henlius Biotech, Bio-Thera Solutions, Dr. Reddy's Laboratories, Alvotech, Biocon Biologics, and Organon. Companies are focusing on regulatory approvals, biosimilar development, partnerships, and new formulations.
Conclusion
The pembrolizumab market is projected to grow from USD 31.70 billion in 2025 to USD 33.10 billion in 2026, reaching USD 41.10 billion by 2034. Growth will be supported by label expansion, rising cancer incidence, biomarker-driven therapy adoption, and subcutaneous formulation launches. However, high treatment costs, reimbursement barriers, and future biosimilar competition may moderate long-term growth.
Segmentation By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Region
By Product Type * KEYTRUDA IV
- KEYTRUDA QLEX / SC Pembrolizumab
By Disease Indication * NSCLC
- Melanoma
- HNSCC
- Urothelial Carcinoma
- RCC
- TNBC
- Gastric/GEJ/Esophageal Cancers
- Cervical Cancer
- Others
By Age Group * Pediatric
- Others
By Type * Branded
- Biosimilar
By Therapy Setting * Early-stage / Perioperative
- Advanced / Metastatic
- Others
By Route of Administration * IV
- SC
By End User * Hospitals
- Specialty Cancer Clinics
- Ambulatory Infusion Centers
- Others
By Region * North America (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country)
- U.S.
- Canada
- Europe (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Product Type, Disease Indication, Age Group, Type, Therapy Setting, Route of Administration, End User, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. New Product Launches, By Key Players
- 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
- 4.3. Regulatory & Reimbursement Scenario, By Key Countries/Regions
- 4.4. Pipeline Analysis, By Key Players
5. Global Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Product Type
- 5.1.1. KEYTRUDA IV
- 5.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 5.2. Market Analysis, Insights and Forecast - By Disease Indication
- 5.2.1. NSCLC
- 5.2.2. Melanoma
- 5.2.3. HNSCC
- 5.2.4. Urothelial Carcinoma
- 5.2.5. RCC
- 5.2.6. TNBC
- 5.2.7. Gastric/GEJ/Esophageal Cancers
- 5.2.8. Cervical Cancer
- 5.2.9. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
- 5.4. Market Analysis, Insights and Forecast - By Type
- 5.4.1. Branded
- 5.4.2. Biosimilar
- 5.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 5.5.1. Early-stage / Perioperative
- 5.5.2. Advanced / Metastatic
- 5.5.3. Others
- 5.6. Market Analysis, Insights and Forecast - By Route of Administration
- 5.6.1. IV
- 5.6.2. SC
- 5.7. Market Analysis, Insights and Forecast - By End User
- 5.7.1. Hospitals
- 5.7.2. Specialty Cancer Clinics
- 5.7.3. Ambulatory Infusion Centers
- 5.7.4. Others
- 5.8. Market Analysis, Insights and Forecast - Region
- 5.8.1. North America
- 5.8.2. Europe
- 5.8.3. Asia Pacific
- 5.8.4. Latin America
- 5.8.5. Middle East & Africa
6. North America Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Product Type
- 6.1.1. KEYTRUDA IV
- 6.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 6.2. Market Analysis, Insights and Forecast - By Disease Indication
- 6.2.1. NSCLC
- 6.2.2. Melanoma
- 6.2.3. HNSCC
- 6.2.4. Urothelial Carcinoma
- 6.2.5. RCC
- 6.2.6. TNBC
- 6.2.7. Gastric/GEJ/Esophageal Cancers
- 6.2.8. Cervical Cancer
- 6.2.9. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adults
- 6.4. Market Analysis, Insights and Forecast - By Type
- 6.4.1. Branded
- 6.4.2. Biosimilar
- 6.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 6.5.1. Early-stage / Perioperative
- 6.5.2. Advanced / Metastatic
- 6.5.3. Others
- 6.6. Market Analysis, Insights and Forecast - By Route of Administration
- 6.6.1. IV
- 6.6.2. SC
- 6.7. Market Analysis, Insights and Forecast - By End User
- 6.7.1. Hospitals
- 6.7.2. Specialty Cancer Clinics
- 6.7.3. Ambulatory Infusion Centers
- 6.7.4. Others
- 6.8. Market Analysis, Insights and Forecast - By Country
- 6.8.1. U.S.
- 6.8.2. Canada
7. Europe Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Product Type
- 7.1.1. KEYTRUDA IV
- 7.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 7.2. Market Analysis, Insights and Forecast - By Disease Indication
- 7.2.1. NSCLC
- 7.2.2. Melanoma
- 7.2.3. HNSCC
- 7.2.4. Urothelial Carcinoma
- 7.2.5. RCC
- 7.2.6. TNBC
- 7.2.7. Gastric/GEJ/Esophageal Cancers
- 7.2.8. Cervical Cancer
- 7.2.9. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adults
- 7.4. Market Analysis, Insights and Forecast - By Type
- 7.4.1. Branded
- 7.4.2. Biosimilar
- 7.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 7.5.1. Early-stage / Perioperative
- 7.5.2. Advanced / Metastatic
- 7.5.3. Others
- 7.6. Market Analysis, Insights and Forecast - By Route of Administration
- 7.6.1. IV
- 7.6.2. SC
- 7.7. Market Analysis, Insights and Forecast - By End User
- 7.7.1. Hospitals
- 7.7.2. Specialty Cancer Clinics
- 7.7.3. Ambulatory Infusion Centers
- 7.7.4. Others
- 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.8.1. U.K.
- 7.8.2. Germany
- 7.8.3. France
- 7.8.4. Italy
- 7.8.5. Spain
- 7.8.6. Scandinavia
- 7.8.7. Rest of Europe
8. Asia Pacific Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Product Type
- 8.1.1. KEYTRUDA IV
- 8.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 8.2. Market Analysis, Insights and Forecast - By Disease Indication
- 8.2.1. NSCLC
- 8.2.2. Melanoma
- 8.2.3. HNSCC
- 8.2.4. Urothelial Carcinoma
- 8.2.5. RCC
- 8.2.6. TNBC
- 8.2.7. Gastric/GEJ/Esophageal Cancers
- 8.2.8. Cervical Cancer
- 8.2.9. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adults
- 8.4. Market Analysis, Insights and Forecast - By Type
- 8.4.1. Branded
- 8.4.2. Biosimilar
- 8.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 8.5.1. Early-stage / Perioperative
- 8.5.2. Advanced / Metastatic
- 8.5.3. Others
- 8.6. Market Analysis, Insights and Forecast - By Route of Administration
- 8.6.1. IV
- 8.6.2. SC
- 8.7. Market Analysis, Insights and Forecast - By End User
- 8.7.1. Hospitals
- 8.7.2. Specialty Cancer Clinics
- 8.7.3. Ambulatory Infusion Centers
- 8.7.4. Others
- 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.8.1. China
- 8.8.2. Japan
- 8.8.3. India
- 8.8.4. Southeast Asia
- 8.8.5. Australia
- 8.8.6. Rest of Asia Pacific
9. Latin America Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Product Type
- 9.1.1. KEYTRUDA IV
- 9.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 9.2. Market Analysis, Insights and Forecast - By Disease Indication
- 9.2.1. NSCLC
- 9.2.2. Melanoma
- 9.2.3. HNSCC
- 9.2.4. Urothelial Carcinoma
- 9.2.5. RCC
- 9.2.6. TNBC
- 9.2.7. Gastric/GEJ/Esophageal Cancers
- 9.2.8. Cervical Cancer
- 9.2.9. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adults
- 9.4. Market Analysis, Insights and Forecast - By Type
- 9.4.1. Branded
- 9.4.2. Biosimilar
- 9.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 9.5.1. Early-stage / Perioperative
- 9.5.2. Advanced / Metastatic
- 9.5.3. Others
- 9.6. Market Analysis, Insights and Forecast - By Route of Administration
- 9.6.1. IV
- 9.6.2. SC
- 9.7. Market Analysis, Insights and Forecast - By End User
- 9.7.1. Hospitals
- 9.7.2. Specialty Cancer Clinics
- 9.7.3. Ambulatory Infusion Centers
- 9.7.4. Others
- 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.8.1. Brazil
- 9.8.2. Mexico
- 9.8.3. Rest of Latin America
10. Middle East & Africa Pembrolizumab Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Product Type
- 10.1.1. KEYTRUDA IV
- 10.1.2. KEYTRUDA QLEX / SC Pembrolizumab
- 10.2. Market Analysis, Insights and Forecast - By Disease Indication
- 10.2.1. NSCLC
- 10.2.2. Melanoma
- 10.2.3. HNSCC
- 10.2.4. Urothelial Carcinoma
- 10.2.5. RCC
- 10.2.6. TNBC
- 10.2.7. Gastric/GEJ/Esophageal Cancers
- 10.2.8. Cervical Cancer
- 10.2.9. Others
- 10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adults
- 10.4. Market Analysis, Insights and Forecast - By Type
- 10.4.1. Branded
- 10.4.2. Biosimilar
- 10.5. Market Analysis, Insights and Forecast - By Therapy Setting
- 10.5.1. Early-stage / Perioperative
- 10.5.2. Advanced / Metastatic
- 10.5.3. Others
- 10.6. Market Analysis, Insights and Forecast - By Route of Administration
- 10.6.1. IV
- 10.6.2. SC
- 10.7. Market Analysis, Insights and Forecast - By End User
- 10.7.1. Hospitals
- 10.7.2. Specialty Cancer Clinics
- 10.7.3. Ambulatory Infusion Centers
- 10.7.4. Others
- 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.8.1. GCC
- 10.8.2. South Africa
- 10.8.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Merck & Co., Inc.
- 11.2.2. Samsung Bioepis Co., Ltd.
- 11.2.3. Sandoz AG
- 11.2.4. Celltrion, Inc.
- 11.2.5. Shanghai Henlius Biotech, Inc.
- 11.2.6. Bio-Thera Solutions, Ltd.
- 11.2.7. Dr. Reddy's Laboratories Ltd.
- 11.2.8. Alvotech
- 11.2.9. Biocon Biologics Limited
- 11.2.10. Organon & Co.
